A true positive prediction involved combining mirvetuximab soravtansine (anti-FOLR1 + tubulin inhibitor) with bevacizumab (anti-VEGFA) in platinum-resistant ovarian cancer. Here, FOLR1 is linked to ovarian carcinoma.